TAC01-HER2 for HER2 Positive Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
HER2 Positive Breast CancerTAC01-HER2 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). The purpose of the trial is to establish the safety, maximum tolerated dose, and efficacy of the therapy in subjects with relapsed or refractory solid tumors.

Eligible Conditions
  • HER2 Positive Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
MT-5111 (experimental study drug)
1
ZW49
1
²¹²Pb-DOTAM-GRPR1

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 1, 3, 6, 9, 12, 18 and 24 months

Month 24
Evaluate Overall Response Rate (ORR)
24 Months
Determine expansion of TAC01-HER2
Determine persistence of TAC01-HER2
Evaluate Overall Survival (OS)
Incidence of Treatment-Emergent Adverse Events
28-42 Days Post-Treatment
Determine MTD or RP2D

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
MT-5111 (experimental study drug)
1
ZW49
1
²¹²Pb-DOTAM-GRPR1

Trial Design

1 Treatment Group

TAC01-HER2
1 of 1

Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: TAC01-HER2 · No Placebo Group · Phase 1 & 2

TAC01-HER2
Biological
Experimental Group · 1 Intervention: TAC01-HER2 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1, 3, 6, 9, 12, 18 and 24 months

Who is running the clinical trial?

Triumvira Immunologics, Inc.Lead Sponsor
1 Previous Clinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a recent tumor sample to confirm HER2-protein expression on tumor cell surface.
For breast cancer patients, both prior lines of therapy must include HER2 targeted agents.
You have a measurable disease.\n
You have a performance status of 0 or 1.
You have a normal organ function.
You have relapsed or refractory disease after two or more prior lines of therapy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top